Home › NDC Lookup › RxCUI directory › RxCUI 199655

Zafirlukast 20 MG Oral Tablet — RxCUI 199655

RxNorm drug concept · Semantic clinical drug
RxCUI 199655 Semantic clinical drug · SCD ● Current RxNorm concept 12 FDA products 24 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI199655
Official nameZafirlukast 20 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped12
Package NDCs mapped24
Reported Medicaid activity (SDUD)7,352 prescriptions · 35 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Zafirlukast: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • No, it's quite different from a rescue inhaler. Zafirlukast is a daily tablet that works in the background to prevent asthma symptoms by blocking chemicals in your body called leuk...
  • What exactly does zafirlukast do — is it the same as an inhaler?
  • Timing really does matter here. Food can reduce how much zafirlukast your body actually absorbs by about 40%, which means it could be a lot less effective if you take it with a mea...
  • Does it matter when I take it — can I just take it with breakfast?
📖 Read our full Zafirlukast guide →

🕸️ Concept Web — How Zafirlukast 20 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Zafirlukast 20 MG Oral Tablet RxCUI 199655

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Zafirlukast 114970
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Accolate 135092
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Zafirlukast Oral Tablet 374330
    • Zafirlukast Oral Product 1165263
    • Zafirlukast Pill 1165264
    • Zafirlukast Oral Tablet [Accolate] 367658
    • Accolate Oral Product 1165968
    • Accolate Pill 1165969
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Zafirlukast 20 MG 316914
    • Zafirlukast 20 MG Oral Tablet [Accolate] 211776
    • Zafirlukast 20 MG [Accolate] 572109

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Zafirlukast 20 MG SCDC · 316914
  • Zafirlukast Oral Tablet SCDF · 374330
  • Zafirlukast Oral Product SCDG · 1165263
  • Zafirlukast Pill SCDG · 1165264

Brand-Name Concepts

  • Zafirlukast 20 MG Oral Tablet [Accolate] SBD · 211776
  • Zafirlukast 20 MG [Accolate] SBDC · 572109
  • Zafirlukast Oral Tablet [Accolate] SBDF · 367658
  • Accolate Oral Product SBDG · 1165968
  • Accolate Pill SBDG · 1165969
  • Accolate BN · 135092

📦 FDA Products & Package NDCs

12 products · 24 package NDCs
24 package NDCs map to RxCUI 199655 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
31722-0007-01 10 BLISTER PACK in 1 CARTON (31722-007-01) / 10 TABLET, FIL... Zafirlukast Camber Pharmaceuticals, Inc. 2020-09-10
31722-0007-05 500 TABLET, FILM COATED in 1 BOTTLE (31722-007-05) Zafirlukast Camber Pharmaceuticals, Inc. 2020-09-10
31722-0007-60 60 TABLET, FILM COATED in 1 BOTTLE (31722-007-60) Zafirlukast Camber Pharmaceuticals, Inc. 2020-09-10
31722-0008-01 10 BLISTER PACK in 1 CARTON (31722-008-01) / 10 TABLET, FIL... Zafirlukast Camber Pharmaceuticals, Inc. 2020-09-10
31722-0008-05 500 TABLET, FILM COATED in 1 BOTTLE (31722-008-05) Zafirlukast Camber Pharmaceuticals, Inc. 2020-09-10
31722-0008-60 60 TABLET, FILM COATED in 1 BOTTLE (31722-008-60) Zafirlukast Camber Pharmaceuticals, Inc. 2020-09-10
42291-0970-60 60 TABLET, COATED in 1 BOTTLE (42291-970-60) Zafirlukast AvKARE 2023-04-05
42291-0971-60 60 TABLET, COATED in 1 BOTTLE (42291-971-60) Zafirlukast AvKARE 2023-04-05
55111-0625-01 100 TABLET, FILM COATED in 1 BOTTLE (55111-625-01) Zafirlukast Dr. Reddys Laboratories Limited 2010-11-18
55111-0625-05 500 TABLET, FILM COATED in 1 BOTTLE (55111-625-05) Zafirlukast Dr. Reddys Laboratories Limited 2010-11-18
55111-0625-30 30 TABLET, FILM COATED in 1 BOTTLE (55111-625-30) Zafirlukast Dr. Reddys Laboratories Limited 2010-11-18
55111-0625-60 60 TABLET, FILM COATED in 1 BOTTLE (55111-625-60) Zafirlukast Dr. Reddys Laboratories Limited 2010-11-18
55111-0625-78 10 BLISTER PACK in 1 CARTON (55111-625-78) / 10 TABLET, FIL... Zafirlukast Dr. Reddys Laboratories Limited 2010-11-18
55111-0626-01 100 TABLET, FILM COATED in 1 BOTTLE (55111-626-01) Zafirlukast Dr. Reddys Laboratories Limited 2010-11-18
55111-0626-05 500 TABLET, FILM COATED in 1 BOTTLE (55111-626-05) Zafirlukast Dr. Reddys Laboratories Limited 2010-11-18
55111-0626-30 30 TABLET, FILM COATED in 1 BOTTLE (55111-626-30) Zafirlukast Dr. Reddys Laboratories Limited 2010-11-18
55111-0626-60 60 TABLET, FILM COATED in 1 BOTTLE (55111-626-60) Zafirlukast Dr. Reddys Laboratories Limited 2010-11-18
55111-0626-78 10 BLISTER PACK in 1 CARTON (55111-626-78) / 10 TABLET, FIL... Zafirlukast Dr. Reddys Laboratories Limited 2010-11-18
59651-0291-60 60 TABLET, FILM COATED in 1 BOTTLE (59651-291-60) Zafirlukast Aurobindo Pharma Limited 2023-11-27
59651-0292-60 60 TABLET, FILM COATED in 1 BOTTLE (59651-292-60) Zafirlukast Aurobindo Pharma Limited 2023-11-27
64380-0187-01 60 TABLET, COATED in 1 BOTTLE (64380-187-01) Zafirlukast Strides Pharma Science Limited 2022-09-15
64380-0188-01 60 TABLET, COATED in 1 BOTTLE (64380-188-01) Zafirlukast Strides Pharma Science Limited 2022-08-01
68084-0059-21 30 BLISTER PACK in 1 BOX, UNIT-DOSE (68084-059-21) / 1 TABL... Zafirlukast American Health Packaging 2013-06-03
72162-2361-06 60 TABLET, FILM COATED in 1 BOTTLE (72162-2361-6) Zafirlukast Bryant Ranch Prepack 2024-06-28
Observed labelers: Dr. Reddys Laboratories Limited (10) · Camber Pharmaceuticals, Inc. (6) · Aurobindo Pharma Limited (2) · AvKARE (2) · Strides Pharma Science Limited (2) · American Health Packaging (1) · +1 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.